| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 06/16/2004 | EP1427395A1 Stabilization of active agents by formulation into nanoparticulate form |
| 06/16/2004 | EP1427394A1 Process for accelerating recovery from trauma by using apoptosis-mimicking synthetic or natural entities |
| 06/16/2004 | EP1427392A1 New self emulsifying drug delivery system |
| 06/16/2004 | EP1427391A1 Vascular occlusion solid-phase agent with immobilised platelet binding agent |
| 06/16/2004 | EP1427390A1 Drug delivery system |
| 06/16/2004 | EP1427383A1 Compositions and methods relating to prevention of chemotherapy-induced alopecia |
| 06/16/2004 | EP1427379A2 Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis |
| 06/16/2004 | EP1427377A2 Methods and compositions for treating or preventing skin disorders using binding agents specific for prostate specific membrane antigen |
| 06/16/2004 | EP1427366A2 Vaginal delivery of chemotherapeutic agents and inhibitors of membrane efflux systems for cancer therapy |
| 06/16/2004 | EP1427326A2 Combination therapy for the treatment of cancer |
| 06/16/2004 | EP1427323A2 Use of s-nitrosothiol signaling to treat disordered control of breathing |
| 06/16/2004 | EP1427289A2 Pulsatile release compositions and methods for enhanced gastrointestinal drug absorption |
| 06/16/2004 | EP1427287A1 Pesticidal and parasitical di-and trifluorosubstituted alkene compounds |
| 06/16/2004 | EP1355646A4 Muscarinic receptor agonists |
| 06/16/2004 | EP1351958B1 Imidazolo-5-yl-2-anilino-pyrimidines as agents for the inhibition of the cell proliferation |
| 06/16/2004 | EP1339719B1 Benzimidazole derivatives, preparation and therapeutic use thereof |
| 06/16/2004 | EP1339406B1 Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders |
| 06/16/2004 | EP1326622A4 Compositions and methods for treatment of multiple myeloma |
| 06/16/2004 | EP1315731B1 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives |
| 06/16/2004 | EP1294413B1 Sprayable wound care compositions |
| 06/16/2004 | EP1294364A4 Stable gabapentin having ph within a controlled range |
| 06/16/2004 | EP1282616B1 Hydroxyphenyl-piperidin-4-ylidene-methyl-benzamide derivatives for the treatement of pain |
| 06/16/2004 | EP1268469B1 N-(heterocyclyl)benzene or pyridine sulphonamides as antithrombotic agents and anticoagulants |
| 06/16/2004 | EP1268387B1 Specific salt forms of triphenylethylene derivatives as selective estrogen receptor modulators |
| 06/16/2004 | EP1267833B1 Pharmaceutical preparations and their manufacture |
| 06/16/2004 | EP1263751B1 2-phenylpyran-4-one derivatives |
| 06/16/2004 | EP1261344B1 Use of indoloquinoxalines for the treatment of multiple sklerosis |
| 06/16/2004 | EP1257556B1 Thiazolopyrimidines and their use as modulators of chemokine receptor activity |
| 06/16/2004 | EP1257267B1 Composition for the prevention and/or treatment of lipid metabolism disorders and allergic forms |
| 06/16/2004 | EP1255751B1 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b or v1b and v1a arginine-vasopressin receptors |
| 06/16/2004 | EP1244643B1 Tryptase inhibitors |
| 06/16/2004 | EP1235777B1 Vitamin d analogues |
| 06/16/2004 | EP1233772A4 Boron compounds and complexes as anti-inflammatory agents |
| 06/16/2004 | EP1221950B1 Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog |
| 06/16/2004 | EP1218401B1 4-benzylaminoquinoline conjugates with bile acid and their heteroanalogues, methods for producing the same, medicaments containing these compounds and their use |
| 06/16/2004 | EP1214075B1 POLYMORPHS OF N-METHYL-N-(3- 3- 2-THIENYLCARBONYL]-PYRAZOL- 1,5-$g(a)]-PYRIMIDIN-7-YL PHENYL)ACETAMIDE AND COMPOSITIONS AND METHODS RELATED THERETO |
| 06/16/2004 | EP1214074B1 Dioxolane nucleoside analogs for the treatment or prevention of viral infection |
| 06/16/2004 | EP1200096B1 Tixocortol pivalate suspension, mouth-wash based thereon and packaging containing same |
| 06/16/2004 | EP1196418B1 METHOD FOR PREPARING SUBSTITUTED 1,4]DIAZEPINO 6,7,1- i hi /i ]INDOL-4-ONES |
| 06/16/2004 | EP1194411B1 Benzoylpyridazines |
| 06/16/2004 | EP1194132B1 Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof |
| 06/16/2004 | EP1165044B1 High potency dihydroergotamine compositions |
| 06/16/2004 | EP1147083B1 Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression |
| 06/16/2004 | EP1144425B1 Derivatives of monosaccharides as cell adhesion inhibitors |
| 06/16/2004 | EP1140127B1 Antiprotozoal saponins |
| 06/16/2004 | EP1140068B1 Doramectin formulations |
| 06/16/2004 | EP1140032B1 A pharmaceutical mixture comprising a profen |
| 06/16/2004 | EP1121106B1 Treatment of indigestion |
| 06/16/2004 | EP1119570B1 Tricyclic delta3-piperidines as pharmaceuticals |
| 06/16/2004 | EP1117408B1 Use of diltiazem for treating retinal pathologies |
| 06/16/2004 | EP1109810B1 Benzonaphthyridine-n-oxides comprising a pde3 and pde4 inhibiting activity |
| 06/16/2004 | EP1100476B1 Formulations for the transdermal administration of fenoldopam |
| 06/16/2004 | EP1098649B1 Method for stabilizing pharmaceutical compositions by special use of an antioxidant |
| 06/16/2004 | EP1089963B1 Hydroxamic acid derivatives as inhibitors of the production of human cd23 and of the tnf release |
| 06/16/2004 | EP1082109B1 Oral formulation comprising biguanide and an organic acid |
| 06/16/2004 | EP1071658B1 Btk inhibitors and methods for their identification and use |
| 06/16/2004 | EP1071413B1 Topical formulations for the treatment of nail fungal diseases |
| 06/16/2004 | EP1064942B1 Sustained release preparation of a macrolide |
| 06/16/2004 | EP1064404B1 P53-regulated genes |
| 06/16/2004 | EP1058552B1 Steroid derived antibiotics |
| 06/16/2004 | EP1056745B1 6,9-disubstituted 2- trans-(4- aminocyclohexyl) amino]purines |
| 06/16/2004 | EP1030670B1 Use of vitamin d derivatives to enhance efficacy of cytotoxic agents |
| 06/16/2004 | EP1027053B1 Method of preventing nephrotoxicity caused by cyclosporins or tacrolimus |
| 06/16/2004 | EP1014961B1 Treatment of migraine headache using metoclopramide and an nsaid |
| 06/16/2004 | EP0994889B1 Erythromycin a oxime solvates |
| 06/16/2004 | EP0986381B1 Use of diterpenes like hypoestoxides for the manufacture of a medicament for immunosuppression, anticancer and antiviral treatment |
| 06/16/2004 | EP0983243B1 Novel quinoline- and naphthalenecarboxamides, pharmaceutical compositions and methods of inhibiting calpain |
| 06/16/2004 | EP0981354B1 Condensation polymer composition for preventing pregnancy |
| 06/16/2004 | EP0979079B1 Use of tetrahydropyridine derivatives to prepare medicines for treating diseases causing demyelination |
| 06/16/2004 | EP0977725B1 New fatty acid derivatives |
| 06/16/2004 | EP0977554B1 Confectionery compositions |
| 06/16/2004 | EP0973730B1 Calcilytic compounds |
| 06/16/2004 | EP0960104B1 N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-one derivatives as factor xa inhibitors |
| 06/16/2004 | EP0923399B1 Kit of parts comprising three vials for embolizing vascular sites with an embolizing composition comprising dimethylsulfoxide |
| 06/16/2004 | EP0906102B1 A process for regulating vagal tone |
| 06/16/2004 | EP0902777B2 D-mannitol and its preparation |
| 06/16/2004 | EP0897919B1 Novel pyridonecarboxylic acid derivatives or salts thereof and antibacterial agents containing the same as the active ingredient |
| 06/16/2004 | EP0817635B1 Use of thiazepine, oxazepine and diazepine coumpounds for inhibiting hiv, herpesvirus and suppressing the immune system |
| 06/16/2004 | EP0815080B1 Di-substituted 1,4-piperidine esters and amides having 5-ht4 antagonistic activity |
| 06/16/2004 | EP0807105B1 Pyridopyrimidones, quinolines and fused n-heretocycles as bradykinin antagonists |
| 06/16/2004 | EP0789563B1 Hepatitis virus b and c vaccines |
| 06/16/2004 | EP0788308B1 Polymeric wound healing accelerators |
| 06/16/2004 | EP0787003B1 Animal model system for the testing of drug candidates for the treatment of leukemia or hiv |
| 06/16/2004 | EP0672133B1 TNF-alpha RIBOZYMES AND DEGRADATION RESISTANT mRNA DERIVATIVES LINKED TO TNF-alpha RIBOZYMES |
| 06/16/2004 | CN1505646A Facially amphiphilic polymers as anti-infective agents |
| 06/16/2004 | CN1505636A Pharmaceutically active uridine esters |
| 06/16/2004 | CN1505635A Method for the synthesis of 2',3'-dideoxy-2',3'-didehydronucleosides |
| 06/16/2004 | CN1505634A Methods utilizing aryl thioimines in synthesis of erythromycin derivatives |
| 06/16/2004 | CN1505633A Anhydrous crystal of beta-lactam compound and method for producing the same |
| 06/16/2004 | CN1505631A Substituted pyrazinoquinoxaline derivatives as serotonin receptor agonist and antagonists ligands |
| 06/16/2004 | CN1505629A Clathrate of azithromycin hydrate with 1,2-propyleneglycol, method for the manufacture thereof and pharmaceutical composition comprising same |
| 06/16/2004 | CN1505628A Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
| 06/16/2004 | CN1505627A Cyclic amp-specific phosphodiesterase inhibitors |
| 06/16/2004 | CN1505626A Novel benzylpiperidine compound |
| 06/16/2004 | CN1505625A Triazole compounds useful in treating diseases associated with unwanted cytokine activity |
| 06/16/2004 | CN1505624A Piperazino-derivatives and their use as pde4 inhibitor |
| 06/16/2004 | CN1505623A Benzoaxathiepin derivatives and their use as medicines |
| 06/16/2004 | CN1505619A Preparation of warfarin sodium from warfarin sodium 2-propanol clathrate by nondestructive solvent expulsion |
| 06/16/2004 | CN1505618A Dimeric isoflavones |
| 06/16/2004 | CN1505617A Peptides as met-ap2 inhibitors |